ClinicalTrials.Veeva

Menu

Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

U

University of Sulaimani

Status

Completed

Conditions

Recurrent Urinary Tract Infection

Treatments

Dietary Supplement: Nanotechnology Structured water Magnalife
Dietary Supplement: Ordinary bottled drinking water
Drug: Trimethoprim

Study type

Interventional

Funder types

Other

Identifiers

NCT04306731
College of Medicine

Details and patient eligibility

About

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Full description

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Enrollment

437 patients

Sex

Female

Ages

24 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥ 2 (two or more than two) UTI in the last 6 months
  • ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion criteria

  • immunotherapy
  • radiotherapy
  • malignancy
  • steroids
  • chronic infections
  • chemotherapy
  • immunosuppressive drugs
  • anatomical abnormality of the urinary tract
  • surgical operation the urinary tract

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

437 participants in 3 patient groups, including a placebo group

Interventional (Group M)
Experimental group
Description:
The group of patients given nanotechnology structured water magnalife
Treatment:
Dietary Supplement: Nanotechnology Structured water Magnalife
Control (Group T)
Active Comparator group
Description:
The group of patients given Trimethoprim
Treatment:
Drug: Trimethoprim
Placebo (Group O)
Placebo Comparator group
Description:
The group of patients given ordinary bottled drinking water
Treatment:
Dietary Supplement: Ordinary bottled drinking water

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems